Diabetic Kidney Disease: A Report from an ADA Consensus Conference

American Journal of Kidney Diseases

Volumn 64, Issue 4, 2014, Pages 510-533

  Tuttle, Katherine R ^a,m   Bakris, George L ^b   Bilous, Rudolf W ^c   Chiang, Jane L ^d   De Boer, Ian H ^a   Goldstein Fuchs, Jordi ^e   Hirsch, Irl B ^a   Kalantar Zadeh, Kamyar ^f   Narva, Andrew S ^g   Navaneethan, Sankar D ^h   Neumiller, Joshua J ⁱ   Patel, Uptal D ^j   Ratner, Robert E ^d   Whaley Connell, Adam T ^k,n   Molitch, Mark E ^l  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d AMERICAN DIABETES ASSOCIATION   (United States)

^e Sierra Nevada Nephrology Consultants   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ WASHINGTON STATE UNIVERSITY   (United States)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^k VETERANS AFFAIRS MEDICAL CENTER   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m Providence Medical Center   (United States)

ⁿ University of Missouri   (United States)

more..

Author keywords

cardiovascular disease; chronic kidney disease (CKD); diabetes mellitus; diabetic kidney disease (DKD); end stage renal disease (ESRD); glycemia; hypertension; medical home; nutrition

Indexed keywords

ANTILIPEMIC AGENT; GLUCOSE; MINERALOCORTICOID ANTAGONIST; ANTIDIABETIC AGENT;

AFRICAN AMERICAN; AMERICAN INDIAN; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONSENSUS; COST OF ILLNESS; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; END STAGE RENAL DISEASE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE DELIVERY; HIGH RISK POPULATION; HISPANIC; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PATIENT MONITORING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ADOLESCENT; ADULT; CLASSIFICATION; CLINICAL TRIAL (TOPIC); COMORBIDITY; COMPLICATION; CONSENSUS DEVELOPMENT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; ETHNIC GROUP; KIDNEY FUNCTION TEST; PHYSIOLOGIC MONITORING; PRACTICE GUIDELINE; PREVALENCE; PROCEDURES; RISK FACTOR;

ADOLESCENT; ADULT; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DELIVERY OF HEALTH CARE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; ETHNIC GROUPS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FUNCTION TESTS; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS;

EID: 84908094488     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.08.001     Document Type: Article

References (190)

1. I.H. de Boer, T.C. Rue, Y.N. Hall, P.J. Heagerty, N.S. Weiss, and J. Himmelfarb Temporal trends in the prevalence of diabetic kidney disease in the United States JAMA 305 2011 2532 2539
2. A.J. Collins, R.N. Foley, and B. Chavers US Renal Data System 2013 annual data report Am J Kidney Dis 63 suppl 1 2014 e219 e220
3. A.J. Collins, R.N. Foley, and B. Chavers US Renal Data System 2013 annual data report Am J Kidney Dis 63 suppl 1 2014 e112 e116
4. National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease Am J Kidney Dis 49 suppl 2 2007 S12 S154
5. G.M. Magee, R.W. Bilous, C.R. Cardwell, S.J. Hunter, F. Kee, and D.G. Fogarty Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis Diabetologia 52 2009 691 697
6. R. Zatz, B.R. Dunn, T.W. Meyer, S. Anderson, H.G. Rennke, and B.M. Brenner Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension J Clin Invest 77 1986 1925 1930
7. M. Evans, S.C. Bain, S. Hogan, R.W. Bilous Collaborative Study Group Participants Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial Nephrol Dial Transplant 27 2012 2255 2263
8. F.A. Holtkamp, D. de Zeeuw, and M.C. Thomas An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function Kidney Int 80 2011 282 287
9. G.L. Bakris, and M. Molitch Microalbuminuria as a risk predictor in diabetes: the continuing saga Diabetes Care 37 2014 867 875
10. R. Bilous Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 25 suppl 2 2008 25 29
11. R. Nosadini, M. Velussi, and E. Brocco Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate Diabetes 49 2000 476 484
12. R.J. MacIsaac, C. Tsalamandris, S. Panagiotopoulos, T.J. Smith, K.J. McNeil, and G. Jerums Nonalbuminuric renal insufficiency in type 2 diabetes Diabetes Care 27 2004 195 200
13. F. He, X. Xia, X.F. Wu, X.Q. Yu, and F.X. Huang Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis Diabetologia 56 2013 457 466
14. L.M. Bachmann, G. Nilsson, and D.E. Bruns State of the art for measurement of urine albumin: comparison of routine measurement procedures to isotope dilution tandem mass spectrometry Clin Chem 60 2014 471 480
15. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
16. A. Patel, S. MacMahon, J. Chalmers ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
17. R.W. Bilous, H.-H. Parving, and T.J. Orchard Renin angiotensin system blockade is effective in preventing microalbuminuria in hypertensive but not normotensive people with type 2 diabetes; further analysis of the DIRECT Programme 2010 EASD Stockholm, Sweden
18. S.H. Saydah, M.E. Pavkov, and C. Zhang Albuminuria prevalence in first morning void compared with previous random urine from adults in the National Health and Nutrition Examination Survey, 2009-2010 Clin Chem 59 2013 675 683
19. B.A. Perkins, L.H. Ficociello, K.H. Silva, D.M. Finkelstein, J.H. Warram, and A.S. Krolewski Regression of microalbuminuria in type 1 diabetes N Engl J Med 348 2003 2285 2293
20. American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 37 suppl 1 2014 S14 S80
21. National Kidney Disease Education Program. Available from: http://nkdep.nih.gov/. Accessed 19 May 2014.
22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Kidney Int 3 2013 S1 S150
23. F. Ismail-Beigi, T. Craven, M.A. Banerji ACCORD trial group Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 2010 419 430
24. P. Rossing Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005 Diabetologia 49 2006 11 19
25. A. Qaseem, R.H. Hopkins Jr., D.E. Sweet, M. Starkey, P. Shekelle Clinical Guidelines Committee of the American College of Physicians Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians Ann Intern Med 159 2013 835 847
26. C.S. Fox, K. Matsushita, M. Woodward Chronic Kidney Disease Prognosis Consortium Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis Lancet 380 2012 1662 1673
27. M. Tonelli, P. Muntner, A. Lloyd Alberta Kidney Disease Network Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study Lancet 380 2012 807 814
28. P.-H. Groop, M.C. Thomas, J.L. Moran FinnDiane Study Group The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes Diabetes 58 2009 1651 1658
29. M. Afkarian, M.C. Sachs, and B. Kestenbaum Kidney disease and increased mortality risk in type 2 diabetes J Am Soc Nephrol 24 2013 302 308
30. K. Borch-Johnsen, P.K. Andersen, and T. Deckert The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus Diabetologia 28 1985 590 596
31. M. Tonelli, P. Muntner, A. Lloyd Alberta Kidney Disease Network Association between LDL-C and risk of myocardial infarction in CKD J Am Soc Nephrol 24 2013 979 986
32. S.C. Palmer, J.C. Craig, S.D. Navaneethan, M. Tonelli, F. Pellegrini, and G.F.M. Strippoli Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis Ann Intern Med 157 2012 263 275
33. R. Haynes, D. Lewis, and J. Emberson Effects of lowering LDL cholesterol on progression of kidney disease J Am Soc Nephrol 25 8 2014 1825 1833
34. C. Wanner, M. Tonelli, and A. Cass KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient Kidney Int 85 2014 1303 1309
35. H. Holdaas, B. Fellström, E. Cole Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study Am J Transplant 5 2005 2929 2936
36. M. Jun, B. Zhu, and M. Tonelli Effects of fibrates in kidney disease: a systematic review and meta-analysis J Am Coll Cardiol 60 2012 2061 2071
37. J.-C. Ansquer, R.N. Dalton, E. Caussé, D. Crimet, K. Le Malicot, and C. Foucher Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people Am J Kidney Dis 51 2008 904 913
38. D.C. Wheeler, and G.J. Becker Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int 83 2013 377 383
39. P.A. James, S. Oparil, and B.L. Carter 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
40. S.J. Taler, R. Agarwal, and G.L. Bakris KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD Am J Kidney Dis 62 2013 201 213
41. V. Pogue, M. Rahman, M. Lipkowitz African American Study of Kidney Disease and Hypertension Collaborative Research Group Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease Hypertension 53 2009 20 27
42. F.H. Messerli, G. Mancia, and C.R. Conti Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144 2006 884 893
43. C.A. Peralta, K.C. Norris, S. Li KEEP Investigators Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP) Arch Intern Med 172 2012 41 47
44. C.P. Kovesdy, A.J. Bleyer, and M.Z. Molnar Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study Ann Intern Med 159 2013 233 242
45. Wake Forest Baptist Health. Systolic Blood Pressure Intervention Trial. Available from: http://clinicaltrials.gov/ct2/show/NCT01206062?term=nct01206062&rank=1. Accessed 19 May 2014.
46. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde The Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
47. B.M. Brenner, M.E. Cooper, D. de Zeeuw RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
48. E.J. Lewis, L.G. Hunsicker, W.R. Clarke Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
49. L.F. Fried, N. Emanuele, J.H. Zhang VA NEPHRON-D Investigators Combined angiotensin inhibition for the treatment of diabetic nephropathy N Engl J Med 369 2013 1892 1903
50. H.-H. Parving, B.M. Brenner, J.J.V. McMurray ALTITUDE Investigators Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med 367 2012 2204 2213
51. J.F.E. Mann, R.E. Schmieder, M. McQueen ONTARGET investigators Renal Outcomes With Telmisartan, Ramipril, or Both, in People at High Vascular Risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 2008 547 553
52. European Medicines Agency. Renin-angiotensin-system (RAS)-acting agents. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Renin-angiotensin-system-(RAS)-acting-agents/human-referral-prac-000026.jsp&mid=WC0b01ac05805c516f. Accessed 19 May 2014.
53. U.F. Mehdi, B. Adams-Huet, P. Raskin, G.L. Vega, and R.D. Toto Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy J Am Soc Nephrol 20 2009 2641 2650
54. B. Pitt, G. Bakris, L.M. Ruilope, L. DiCarlo, R. Mukherjee EPHESUS Investigators Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Circulation 118 2008 1643 1650
55. R.D. Toto RAS blockade, hyperkalemia and AKI - look and you will find Nat Rev Nephrol 8 2012 257 258
56. D.E. Kohan, Y. Pritchett, and M. Molitch Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy J Am Soc Nephrol 22 2011 763 772
57. AbbVie. A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study of Diabetic Nephropathy With Atrasentan. Available from: http://clinicaltrials.gov/show/NCT01858532. Accessed 19 May 2014.
58. A. Briasoulis, and G. Bakris The future of interventional management of hypertension: threats and opportunities Curr Vasc Pharmacol 12 2014 69 76
59. D.L. Bhatt, D.E. Kandzari, W.W. O'Neill SYMPLICITY HTN-3 Investigators A controlled trial of renal denervation for resistant hypertension N Engl J Med 370 2014 1393 1401
60. J.D. Bisognano, G. Bakris, and M.K. Nadim Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial J Am Coll Cardiol 58 2011 765 773
61. D.M. Nathan, J. Kuenen, R. Borg, H. Zheng, D. Schoenfeld, R.J. Heine A1c-Derived Average Glucose Study Group Translating the A1C assay into estimated average glucose values Diabetes Care 31 2008 1473 1478
62. A. Ansari, S. Thomas, and D. Goldsmith Assessing glycemic control in patients with diabetes and end-stage renal failure Am J Kidney Dis 41 2003 523 531
63. F.E. Vos, J.B. Schollum, C.V. Coulter, T.C.A. Doyle, S.B. Duffull, and R.J. Walker Red blood cell survival in long-term dialysis patients Am J Kidney Dis 58 2011 591 598
64. 1c levels in patients with chronic renal failure on hemodialysis Intern Med 37 1998 826 830
65. M.E. Miller, D.E. Bonds, and H.C. Gerstein The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study BMJ 340 2010 b5444
66. S. Shurraw, B. Hemmelgarn, M. Lin Alberta Kidney Disease Network Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study Arch Intern Med 171 2011 1920 1927
67. K. Kalantar-Zadeh A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients Diabetes Care 35 2012 1625 1628
68. S.P.B. Ramirez, K.P. McCullough, and J.R. Thumma Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS) Diabetes Care 35 2012 2527 2532
69. W.J. Kim, C.-Y. Park, and K.-B. Lee Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction Diabetes Care 35 2012 281 286
70. M. Inaba, S. Okuno, Y. Kumeda Osaka CKD Expert Research Group Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection J Am Soc Nephrol 18 2007 896 903
71. B.I. Freedman, L. Andries, and Z.K. Shihabi Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients Clin J Am Soc Nephrol 6 2011 1635 1643
72. J.E. Gerich, C. Meyer, H.J. Woerle, and M. Stumvoll Renal gluconeogenesis: its importance in human glucose homeostasis Diabetes Care 24 2001 382 391
73. National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update Am J Kidney Dis 60 2012 850 886
74. I. Mühlhauser, G. Toth, P.T. Sawicki, and M. Berger Severe hypoglycemia in type I diabetic patients with impaired kidney function Diabetes Care 14 1991 344 346
75. A.J. Scheen Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease Expert Opin Drug Metab Toxicol 9 2013 529 550
76. G. Charpentier, J.P. Riveline, and M. Varroud-Vial Management of drugs affecting blood glucose in diabetic patients with renal failure Diabetes Metab 26 suppl 4 2000 73 85
77. N.R. Burrows, Y. Li, and L.S. Geiss Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline Diabetes Care 33 2010 73 77
78. A.I. Adler, R.J. Stevens, S.E. Manley, R.W. Bilous, C.A. Cull, R.R. Holman UKPDS Group Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int 63 2003 225 232
79. N.N. Zammitt, and B.M. Frier Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities Diabetes Care 28 2005 2948 2961
80. R.A. Whitmer, A.J. Karter, K. Yaffe, C.P. Quesenberry Jr., and J.V. Selby Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus JAMA 301 2009 1565 1572
81. F. Ismail-Beigi, E. Moghissi, M. Tiktin, I.B. Hirsch, S.E. Inzucchi, and S. Genuth Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials Ann Intern Med 154 2011 554 559
82. F. Roberts, and G.J. Ryan The safety of metformin in heart failure Ann Pharmacother 41 2007 642 646
83. K.J. Lipska, C.J. Bailey, and S.E. Inzucchi Use of metformin in the setting of mild-to-moderate renal insufficiency Diabetes Care 34 2011 1431 1437
84. Metformin ok in CKD? Drug Ther Bull 52 2014 37
85. K. Kalantar-Zadeh, R.N. Uppot, and K.B. Lewandrowski Case records of the Massachusetts General Hospital. Case 23-2013. A 54-year-old woman with abdominal pain, vomiting, and confusion N Engl J Med 369 2013 374 382
86. S.R. Salpeter, E. Greyber, G.A. Pasternak, and E.E. Salpeter Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database Syst Rev 4 2010 CD002967
87. R. Rachmani, I. Slavachevski, Z. Levi, B. Zadok, Y. Kedar, and M. Ravid Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications Eur J Intern Med 13 2002 428
88. T. Rydberg, A. Jönsson, M. Røder, and A. Melander Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans Diabetes Care 17 1994 1026 1030
89. A. Holstein, A. Plaschke, and E.H. Egberts Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide Diabetes Metab Res Rev 17 2001 467 473
90. A.D. Harrower Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency Clin Pharmacokinet 31 1996 111 119
91. L. Balant, G. Zahnd, A. Gorgia, R. Schwarz, and J. Fabre Pharmacokinetics of glipizide in man: influence of renal insufficiency Diabetologia 9 suppl 1 1973 331 338
92. T. Nagai, M. Imamura, K. Iizuka, and M. Mori Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure Diabetes Res Clin Pract 59 2003 191 194
93. C. Hasslacher Multinational Repaglinide Renal Study Group Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function Diabetes Care 26 2003 886 891
94. K. Budde, H.-H. Neumayer, L. Fritsche, W. Sulowicz, T. Stompôr, and D. Eckland The pharmacokinetics of pioglitazone in patients with impaired renal function Br J Clin Pharmacol 55 2003 368 374
95. M.C. Chapelsky, K. Thompson-Culkin, A.K. Miller, M. Sack, R. Blum, and M.I. Freed Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency J Clin Pharmacol 43 2003 252 259
96. K. Thompson-Culkin, B. Zussman, A.K. Miller, and M.I. Freed Pharmacokinetics of rosiglitazone in patients with end-stage renal disease J Int Med Res 30 2002 391 399
97. A.B. Grey Skeletal toxicity of thiazolidinediones Ann Intern Med 148 2008 563
98. US Food and Drug Administration. Drug safety information for healthcare professionals - information for healthcare professionals: reports of altered kidney function in patients using exenatide (marketed as Byetta). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm188656.htm. Accessed 19 May 2014.
99. K.R. Tuttle, C. Heilmann, B.J. Hoogwerf, C. Brown, and P.W. Anderson Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes Am J Kidney Dis 62 2013 396 398
100. M. Pawaskar, K.R. Tuttle, Q. Li, J.H. Best, and P.W. Anderson Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine Ann Pharmacother 48 2014 571 576
101. J.A. Davidson, J. Brett, A. Falahati, and D. Scott Mild renal impairment and the efficacy and safety of liraglutide Endocr Pract 17 2011 345 355
102. M. Pendergrass, C. Fenton, S.M. Haffner, and W. Chen Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis Diabetes Obes Metab 14 2012 596 600
103. C.F. Deacon, E. Mannucci, and B. Ahrén Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis Diabetes Obes Metab 14 2012 762 767
104. V.R. Aroda, R.R. Henry, and J. Han Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review Clin Ther 34 2012 1247 1258.e22
105. C.B. Giorda, E. Nada, and B. Tartaglino Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature [published correction appears in Endocrine 2014;46:420-22] Endocrine 46 2014 406 419
106. Januvia (sitagliptin) [package insert] February 2014 Merck & Co. Inc. Whitehouse Station, NJ
107. Onglyza (saxagliptin) [package insert] May 2013 Bristol-Myers Squibb Co. Princeton, NJ
108. Nesina (alogliptin) [package insert] June 2013 Takeda Pharmaceuticals American, Inc. Deerfield, IL
109. Tradjenta (linagliptin) [package insert] May 2014 Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT
110. C. Friedrich, A. Emser, H.-J. Woerle, and U. Graefe-Mody Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes Am J Ther 20 2013 618 621
111. Y.G. Kim, S. Hahn, T.J. Oh, S.H. Kwak, K.S. Park, and Y.M. Cho Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis Diabetologia 56 2013 696 708
112. J.J. Neumiller, J.R. White Jr., and R.K. Campbell Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus Drugs 70 2010 377 385
113. D.E. Kohan, P. Fioretto, W. Tang, and J.F. List Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control Kidney Int 85 2014 962 971
114. J.-F. Yale, G. Bakris, and B. Cariou Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 2013 463 473
115. D.Z.I. Cherney, B.A. Perkins, and N. Soleymanlou Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus Circulation 129 2014 587 597
116. C. Meloni, M. Morosetti, and C. Suraci Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr 12 2002 96 101
117. E.M. Wrone, M.R. Carnethon, L. Palaniappan, S.P. Fortmann Third National Health and Nutrition Examination Survey Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 2003 580 587
118. E.K. Hoogeveen, P.J. Kostense, and A. Jager Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study Kidney Int 54 1998 203 209
119. E.L. Knight, M.J. Stampfer, S.E. Hankinson, D. Spiegelman, and G.C. Curhan The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency Ann Intern Med 138 2003 460 467
120. A.M. Bernstein, Q. Sun, F.B. Hu, M.J. Stampfer, J.E. Manson, and W.C. Willett Major dietary protein sources and risk of coronary heart disease in women Circulation 122 2010 876 883
121. Cirillo M, Lombardi C, Chiricone D, De Santo NG, Zanchetti A, Bilancio G. Protein intake and kidney function in the middle-age population: contrast between cross-sectional and longitudinal data [published online ahead of print March 21, 2014]. Nephrol Dial Transplant. http://dx.doi.org/10.1093/ndt/gfu056.
122. R. Estruch, E. Ros, J. Salas-Salvadó PREDIMED Study Investigators Primary prevention of cardiovascular disease with a Mediterranean diet N Engl J Med 368 2013 1279 1290
123. F.M. Sacks, E. Obarzanek, and M.M. Windhauser Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH). A multicenter controlled-feeding study of dietary patterns to lower blood pressure Ann Epidemiol 5 1995 108 118
124. A. Odermatt The Western-style diet: a major risk factor for impaired kidney function and chronic kidney disease Am J Physiol Renal Physiol 301 2011 F919 F931
125. Goldstein-Fuchs DJ, LaPierra AF. Nutrition and Kidney Disease. National Kidney Foundation. National Kidney Foundation's primer on kidney diseases. 6th ed. Gilbert SJ, Weiner DE, Gipson DS, Perazella MA, Tonelli M, Eds. Philadelphia, PA, Elsevier/Saunders, 2014, p. 467-475.
126. L.T.J. Pijls, H. de Vries, J.T.M. van Eijk, and A.J.M. Donker Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial Eur J Clin Nutr 56 2002 1200 1207
127. B. Dussol, C. Iovanna, and D. Raccah A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy J Ren Nutr 15 2005 398 406
128. M.T. Pedrini, A.S. Levey, J. Lau, T.C. Chalmers, and P.H. Wang The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis Ann Intern Med 124 1996 627 632
129. L. Robertson, N. Waugh, and A. Robertson Protein restriction for diabetic renal disease Cochrane Database Syst Rev 4 2007 CD002181
130. H.P. Hansen, P.K. Christensen, E. Tauber-Lassen, A. Klausen, B.R. Jensen, and H.H. Parving Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy Kidney Int 55 1999 621 628
131. B.L. Kasiske, J.D. Lakatua, J.Z. Ma, and T.A. Louis A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function Am J Kidney Dis 31 1998 954 961
132. F.J. Raal, W.J. Kalk, and M. Lawson Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study Am J Clin Nutr 60 1994 579 585
133. R.P. Dullaart, B.J. Beusekamp, S. Meijer, J.J. van Doormaal, and W.J. Sluiter Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension Diabetes Care 16 1993 483 492
134. H.P. Hansen, E. Tauber-Lassen, B.R. Jensen, and H.-H. Parving Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy Kidney Int 62 2002 220 228
135. Y. Pan, L.L. Guo, and H.M. Jin Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials Am J Clin Nutr 88 2008 660 666
136. A.B. Evert, J.L. Boucher, and M. Cypress Nutrition therapy recommendations for the management of adults with diabetes Diabetes Care 37 suppl 1 2014 S120 S143
137. H. Shapiro, M. Theilla, J. Attal-Singer, and P. Singer Effects of polyunsaturated fatty acid consumption in diabetic nephropathy Nat Rev Nephrol 7 2011 110 121
138. C.C. Lee, S.J. Sharp, D.J. Wexler, and A.I. Adler Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and complications trial Diabetes Care 33 2010 1454 1456
139. C.P. Kovesdy, K. Sharma, and K. Kalantar-Zadeh Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis 52 2008 766 777
140. K. Kalantar-Zadeh, K.C. Abbott, F. Kronenberg, S.D. Anker, T.B. Horwich, and G.C. Fonarow Epidemiology of dialysis patients and heart failure patients Semin Nephrol 26 2006 118 133
141. K. Kalantar-Zadeh, G. Block, M.H. Humphreys, and J.D. Kopple Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients Kidney Int 63 2003 793 808
142. K. Kalantar-Zadeh What is so bad about reverse epidemiology anyway? Semin Dial 20 2007 593 601
143. K. Kalantar-Zadeh Causes and consequences of the reverse epidemiology of body mass index in dialysis patients J Ren Nutr 15 2005 142 147
144. K. Kalantar-Zadeh, S.D. Anker, A.J.S. Coats, T.B. Horwich, and G.C. Fonarow Obesity paradox as a component of reverse epidemiology in heart failure Arch Intern Med 165 2005 1797 author reply 1797-1798
145. K. Kalantar-Zadeh, R.D. Kilpatrick, N. Kuwae, and D.Y. Wu Reverse epidemiology: a spurious hypothesis or a hardcore reality? Blood Purif 23 2005 57 63
146. K. Kalantar-Zadeh, R.D. Kilpatrick, C.J. McAllister, S. Greenland, and J.D. Kopple Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions Hypertension 45 2005 811 817
147. G.T. Schumock, D.L. Andress, S.E. Marx, R. Sterz, A.T. Joyce, and K. Kalantar-Zadeh Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients Nephron Clin Pract 113 2009 c54 c61
148. C.M. Rhee, A.M. Leung, C.P. Kovesdy, K.E. Lynch, G.A. Brent, and K. Kalantar-Zadeh Updates on the management of diabetes in dialysis patients Semin Dial 27 2014 135 145
149. J. Park, P. Lertdumrongluk, M.Z. Molnar, C.P. Kovesdy, and K. Kalantar-Zadeh Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon Curr Diab Rep 12 2012 432 439
150. K. Kalantar-Zadeh, S.F. Derose, S. Nicholas, D. Benner, K. Sharma, and C.P. Kovesdy Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus J Ren Nutr 19 2009 33 37
151. J. Ricks, M.Z. Molnar, and C.P. Kovesdy Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study Diabetes 61 2012 708 715
152. K. Kalantar-Zadeh, J.D. Kopple, and D.L. Regidor A1C and survival in maintenance hemodialysis patients Diabetes Care 30 2007 1049 1055
153. J. Hoshino, R. Mehrotra, and C.M. Rhee Using hemoglobin A1c to derive mean blood glucose in peritoneal dialysis patients Am J Nephrol 37 2013 413 420
154. U. Duong, R. Mehrotra, and M.Z. Molnar Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus Clin J Am Soc Nephrol 6 2011 1041 1048
155. M.Z. Molnar, C.P. Kovesdy, and S. Bunnapradist Associations of pretransplant serum albumin with post-transplant outcomes in kidney transplant recipients Am J Transplant 11 2011 1006 1015
156. G. Sarno, R.J. Mehta, R. Guardado-Mendoza, L.M. Jimenez-Ceja, P. De Rosa, and G. Muscogiuri New-onset diabetes mellitus: predictive factors and impact on the outcome of patients undergoing liver transplantation Curr Diabetes Rev 9 2013 78 85
157. H.A. Chakkera, and L.J. Mandarino Calcineurin inhibition and new-onset diabetes mellitus after transplantation Transplantation 95 2013 647 652
158. H.A. Chakkera, E.J. Weil, P.-T. Pham, J. Pomeroy, and W.C. Knowler Can new-onset diabetes after kidney transplant be prevented? Diabetes Care 36 2013 1406 1412
159. TODAY Study Group Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial Diabetes Care 36 2013 1735 1741
160. M.L. Marcovecchio, J. Woodside, T. Jones AdDIT Investigators Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments Diabetes Care 37 2014 805 813
161. F. Demirel, D. Tepe, O. Kara, and I. Esen Microvascular complications in adolescents with type 1 diabetes mellitus J Clin Res Pediatr Endocrinol 5 2013 145 149
162. American Diabetes Association Economic costs of diabetes in the U.S. in 2012 Diabetes Care 36 2013 1033 1046
163. D.J. Pettitt, J. Talton, D. Dabelea SEARCH for Diabetes in Youth Study Group Prevalence of diabetes in U.S. youth in 2009: the SEARCH for Diabetes in Youth Study Diabetes Care 37 2014 402 408
164. D. Dabelea, E.J. Mayer-Davis, S. Saydah SEARCH for Diabetes in Youth Study Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009 JAMA 311 2014 1778 1786
165. P. Gaede, H. Lund-Andersen, H.-H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 2008 580 591
166. P. Gaede, P. Vedel, N. Larsen, G.V.H. Jensen, H.-H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
167. A. Shankar, R. Klein, and B.E.K. Klein The association among smoking, heavy drinking, and chronic kidney disease Am J Epidemiol 164 2006 263 271
168. C.S. Fox, M.G. Larson, E.P. Leip, B. Culleton, P.W.F. Wilson, and D. Levy Predictors of new-onset kidney disease in a community-based population JAMA 291 2004 844 850
169. C. Robinson-Cohen, R. Katz, and D. Mozaffarian Physical activity and rapid decline in kidney function among older adults Arch Intern Med 169 2009 2116 2123
170. P.-Y. Chen, Y.-C. Huang, Y.-H. Kao, and J.-Y. Chen Effects of an exercise program on blood biochemical values and exercise stage of chronic kidney disease patients J Nurs Res 18 2010 98 107
171. Y. Wang, X. Chen, Y. Song, B. Caballero, and L.J. Cheskin Association between obesity and kidney disease: a systematic review and meta-analysis Kidney Int 73 2008 19 33
172. E. Morales, M.A. Valero, M. León, E. Hernández, and M. Praga Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies Am J Kidney Dis 41 2003 319 327
173. J.C. Chan, W.-Y. So, C.-Y. Yeung SURE Study Group Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study Diabetes Care 32 2009 977 982
174. W.Y.S. Leung, W.-Y. So, P.C.Y. Tong, N.N. Chan, and J.C.N. Chan Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy Am J Med 118 2005 1414
175. N.F. Olivarius, H. Beck-Nielsen, A.H. Andreasen, M. Hørder, and P.A. Pedersen Randomised controlled trial of structured personal care of type 2 diabetes mellitus BMJ 323 2001 970 975
176. M.C.E. Rossi, A. Nicolucci, A. Arcangeli Associazione Medici Diabetologi Annals Study Group Baseline quality-of-care data from a quality-improvement program implemented by a network of diabetes outpatient clinics Diabetes Care 31 2008 2166 2168
177. Agency for Healthcare Research and Quality. Patient Self-Management Support Programs. An Evaluation [Internet], 2007. Available from http://www.ahrq.gov/research/findings/final-reports/ptmgmt/index.html. Accessed 19 May 2014.
178. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Sabaté E, Ed. Geneva, World Health Organization, 2003, p. 198.
179. S. Ali, M.A. Stone, J.L. Peters, M.J. Davies, and K. Khunti The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis Diabet Med 23 2006 1165 1173
180. S. Palmer, M. Vecchio, and J.C. Craig Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies Kidney Int 84 2013 179 191
181. C.M. Renders, G.D. Valk, S.J. Griffin, E.H. Wagner, J.T. Eijk Van, and W.J. Assendelft Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review Diabetes Care 24 2001 1821 1833
182. K.G. Shojania, S.R. Ranji, and K.M. McDonald Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis JAMA 296 2006 427 440
183. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group KDIGO clinical practice guideline for lipid management in chronic kidney disease Kidney Int 3 Supp. 2013 259 305
184. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease Kidney Int 2 Supp. 2012 337 414
185. Mitchell P, Wynia M, Golden R, et al. Core principles & values of effective team-based health care, 2012. Washington, DC, Institute of Medicine. Available from: http://www.iom.edu/Global/Perspectives/2012/TeamBasedCare.aspx. Accessed 19 May 2014.
186. B.J. Lee, and K. Forbes The role of specialists in managing the health of populations with chronic illness: the example of chronic kidney disease BMJ 339 2009 b2395
187. B. Lee, M. Turley, and D. Meng Effects of proactive population-based nephrologist oversight on progression of chronic kidney disease: a retrospective control analysis BMC Health Serv Res 12 2012 252
188. E.A. Bayliss, B. Bhardwaja, C. Ross, A. Beck, and D.M. Lanese Multidisciplinary team care may slow the rate of decline in renal function Clin J Am Soc Nephrol 6 2011 704 710
189. T. Bojadzievski, and R.A. Gabbay Patient-centered medical home and diabetes Diabetes Care 34 2011 1047 1053
190. M. Abe, K. Okada, T. Maruyama, N. Maruyama, M. Soma, and K. Matsumoto Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis Expert Opin Pharmacother 11 2010 1611 1620